Effect of milk fermented by Lactobacillus casei CRL431 administered as immune adjuvant against breast cancer metastasis under chemotherapy treatment in a murine model

E. MENDEZ UTZ; A. DE MORENO DE LEBLANC; G. PERDIGON

San Miguel de Tucumán

Congreso; LXVII Reunión Anual de la Sociedad Argentina de Inmunología; 2019

Sociedad Argentina de Inmunología

Chemotherapy is useful to treat breast cancer(BC) metastasis; however, it affects the patients? quality of life. Previously,it was demonstrated that milk fermented by Lactobacilluscasei CRL431 (probiotic fermented milk, PFM) exerted benefits against BCmetastasis by modulating the immune response in a mouse model. Aim: To evaluatePFM administration on the side effects of capecitabine (CAP) and on BCmetastasis treatment in mice. Methods: Invitro, 4T1 BC cells were treated with CAP in presence of immune cells frommice administered PFM or milk. Cell viability was evaluated by MTT assay. In vivo, BALB/c mice (healthy or with BCmetastasis) were treated or not with CAP and administered PFM or milk. Bloodcell counts, small intestine and lung histology and serum cytokines wereevaluated. Results: The toxicity of CAP on 4T1 cells (30% of viability loss)was not affected by the immune cells from mice received PFM. PFM administrationto mice reduced CAP side effects in both healthy and metastatic animals;improved the count of blood cells, and decreased intestinal mucositis. CAPtreatment decreased the lung metastasis and it was associated to decreases ofIL-10, TNF-alpha, IFN-gamma and IL-17. PFM administration to mice underchemotherapy maintained the CAP?s effect with similar or decreased values for thesecytokines. In addition, PFM by itself reduced metastasis without side effectsand improved the host?s immune response. Conclusions: PFM has potential to beadministered as immune adjuvant; can decrease side effects in patients underchemotherapy without affect the treatment